Related references
Note: Only part of the references are listed.Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants
Ilanit Zada et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2021)
Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: A cross-sectional study in patients with atrial fibrillation
Souad Moudallel et al.
PATIENT EDUCATION AND COUNSELING (2021)
Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation
Daehoon Kim et al.
EUROPACE (2021)
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gerhard Hindricks et al.
EUROPEAN HEART JOURNAL (2021)
Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fi brillation: A review
M. Farhan Nasser et al.
HEART RHYTHM (2021)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial
Giuseppe Boriani et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis
SungA Bae et al.
HEART (2021)
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation
Jan Steffel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis
Tarun Dalia et al.
THROMBOSIS JOURNAL (2021)
Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19
Stephanie L. Harrison et al.
JOURNAL OF ARRHYTHMIA (2021)
Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study
Andre Rodrigues Duraes et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2021)
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)
Juhani Knuuti et al.
EUROPEAN HEART JOURNAL (2020)
Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program
John Fanikos et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs
Chun-Li Wang et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2020)
Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials
Tatjana S. Potpara et al.
EUROPACE (2020)
Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage
Jennifer A. Frontera et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
George D. Dangas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children
Leonardo R. Brandao et al.
BLOOD (2020)
Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After an Intracranial Hemorrhage
Nhi Y. Nguyen et al.
CARDIOLOGY IN REVIEW (2020)
Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation A Nationwide Cohort Study
Tze-Fan Chao et al.
CHEST (2020)
The interactions between anticonvulsants and non-vitamin K antagonist oral anticoagulant agents: A systematic review
Mohamed Taha et al.
EPILEPSY RESEARCH (2020)
Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis
Aaqib H. Malik et al.
EUROPACE (2020)
Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis
Benjamin Miao et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Oral anticoagulant and reduced risk of dementia in patients with atrial fibrillation: A population-based cohort study
Pajaree Mongkhon et al.
HEART RHYTHM (2020)
Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis
Toshiki Kuno et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk
S. Windecker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage
So-Ryoung Lee et al.
STROKE (2020)
Early Initiation of Direct Oral Anticoagulants After Onset of Stroke and Short- and Long-Term Outcomes of Patients With Nonvalvular Atrial Fibrillation
Tadataka Mizoguchi et al.
STROKE (2020)
Net clinical benefit of anticoagulation for atrial fibrillation following intracerebral hemorrhage
Matthew A. Pappas et al.
VASCULAR MEDICINE (2020)
Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: Systematic Review of Current Literature
Marvin Kajy et al.
AMERICAN JOURNAL OF THERAPEUTICS (2020)
Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention An Updated Network Meta-analysis
Renato D. Lopes et al.
JAMA CARDIOLOGY (2020)
Acute thrombocytopenia after anticoagulation with rivaroxaban: A case report
Xin-Yi He et al.
WORLD JOURNAL OF CLINICAL CASES (2020)
Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease
Matthew R. Weir et al.
AMERICAN HEART JOURNAL (2020)
Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients
Stephen Y. Wang et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial
Yutao Guo et al.
AMERICAN JOURNAL OF MEDICINE (2020)
Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention A Systematic Review and Meta-analysis
Safi U. Khan et al.
ANNALS OF INTERNAL MEDICINE (2020)
Genetically Elevated LDL Associates with Lower Risk of Intracerebral Hemorrhage
Guido J. Falcone et al.
ANNALS OF NEUROLOGY (2020)
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
John W. Stanifer et al.
CIRCULATION (2020)
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention Insights From AUGUSTUS
John H. Alexander et al.
CIRCULATION (2020)
Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use
So-Ryoung Lee et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2020)
Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study
Paolo Colonna et al.
CLINICAL CARDIOLOGY (2020)
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
Paulus Kirchhof et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis
Shinya Suzuki et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
Christoph Male et al.
LANCET HAEMATOLOGY (2020)
Non-Traumatic Subdural Hemorrhage and Risk of Arterial Ischemic Events
Santosh B. Murthy et al.
STROKE (2020)
Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease
Sean D. Pokorney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Dabigatran initiation in patients with non-valvular AF and first acute ischaemic stroke: a retrospective observational study from the SITS registry
Irene Escudero-Martinez et al.
BMJ OPEN (2020)
Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi
Austin A. Robinson et al.
JAMA CARDIOLOGY (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
V. J. Nijenhuis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019)
Farhad Pazan et al.
DRUGS & AGING (2020)
Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients?
Fabian Sanchis-Gomar et al.
EUROPEAN HEART JOURNAL (2020)
Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation
Yi-Hsin Chan et al.
HEART RHYTHM (2020)
Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation
Hee Tae Yu et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage
Chuan-Tsai Tsai et al.
JAMA NETWORK OPEN (2020)
Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function
Phuong Pham et al.
JAMA NETWORK OPEN (2020)
Outcomes associated with apixaban vs warfarin in patients with renal dysfunction
Claudia Hanni et al.
BLOOD ADVANCES (2020)
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure
Joseph R. Shaw et al.
BLOOD ADVANCES (2020)
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Solution Set Oversight Committee
Gordon F. Tomaselli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation
Pavel Osmancik et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
The 'Ten Commandments' for the 2020 ESC Guidelines for themanagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean-Philippe Collet et al.
EUROPEAN HEART JOURNAL (2020)
Non-vitamin K antagonist oral anticoagulants therapy for atrial fibrillation patients undergoing electrophysiologic procedures
Jan Steffel
EUROPEAN HEART JOURNAL SUPPLEMENTS (2020)
Clinically relevant interaction of rivaroxaban and valproic acid - A case report
Lisa Langenbruch et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2020)
Combining Imaging and Genetics to Predict Recurrence of Anticoagulation-Associated Intracerebral Hemorrhage
Alessandro Biffi et al.
STROKE (2020)
Impacts of Different Renal Function Estimation Formulas on Dosing of DOACs and Clinical Outcomes
Yi-Hsin Chan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
Girish N. Nadkarni et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation
Ken Okumura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
Helio P. Guimaraes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Direct oral anticoagulant use in left ventricular thrombus
Zafar Ali et al.
THROMBOSIS JOURNAL (2020)
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR
Hideyuki Kawashima et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study
Soonil Kwon et al.
AMERICAN HEART JOURNAL (2020)
Determinants of medication adherence in older people with dementia from the caregivers' perspective
Najwan El-Saifi et al.
INTERNATIONAL PSYCHOGERIATRICS (2019)
Prevalence and Resolution of Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation and Flutter With Oral Anticoagulation
Adam D. Niku et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Noncardioembolic Stroke in Patients with Atrial Fibrillation
Vasiliki Katsi et al.
ANGIOLOGY (2019)
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation
Kazuhiko Kido et al.
ANNALS OF PHARMACOTHERAPY (2019)
Progress in the monitoring of direct oral anticoagulant therapy
Jignesh P. Patel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
Craig T. January et al.
CIRCULATION (2019)
Detecting Anti-IIa and Anti-Xa Direct Oral Anticoagulant (DOAC) Agents in Urine using a DOAC Dipstick
Job Harenberg et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2019)
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
Jonas Oldgren et al.
EUROPEAN HEART JOURNAL (2019)
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight
So-Ryoung Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Renato D. Lopes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
S. J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review
Thomas Raphael Meinel et al.
PLOS ONE (2019)
Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation
Malini Madhavan et al.
AMERICAN HEART JOURNAL (2019)
Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation
David J. Seiffge et al.
ANNALS OF NEUROLOGY (2019)
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Stefan H. Hohnloser et al.
EUROPEAN HEART JOURNAL (2019)
Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation
Leif Friberg et al.
EUROPEAN HEART JOURNAL (2019)
The impact of nurse-led atrial fibrillation clinics on patient and healthcare outcomes: a systematic mixed studies review
Kathy L. Rush et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING (2019)
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
Paul Moayyedi et al.
GASTROENTEROLOGY (2019)
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy
Leonardo Di Gennaro et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Cerebral Ischemia in Patients on Direct Oral Anticoagulants Plasma Levels Are Associated With Stroke Severity
Kosmas Macha et al.
STROKE (2019)
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
Peter Bronnum Nielsen et al.
STROKE (2019)
Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016
Geric Maura et al.
BMJ OPEN (2019)
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
Margarita Kushnir et al.
LANCET HAEMATOLOGY (2019)
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF
Sylvia Haas et al.
AMERICAN HEART JOURNAL (2019)
Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation
So-Ryoung Lee et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight Insights From the ARISTOTLE Trial
Stefan H. Hohnloser et al.
CIRCULATION (2019)
Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature
Victor M. Lu et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2019)
Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort
Dongmin Kim et al.
EUROPEAN HEART JOURNAL (2019)
Timing use of novel anti-epileptic drugs: is earlier better?
Stefano de Biase et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)
Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban
Ifeoma Mary Eche et al.
PHARMACOTHERAPY (2019)
Perioperative/Postoperative Atrial Fibrillation and Risk of Subsequent Stroke and/or Mortality: A Meta-Analysis
Meng-Hsin Lin et al.
STROKE (2019)
Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation
Hyun-Jung Lee et al.
STROKE (2019)
Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study
Lucas Yixi Xing et al.
THROMBOSIS RESEARCH (2019)
Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity-Weighted Cohort Study
Mette Sogaard et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Non Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis
Yuqing Deng et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study
Ying Xian et al.
JAMA NEUROLOGY (2019)
Microbleed prevalence and burden in anticoagulant-associated intracerebral bleed
Vasileios-Arsenios Lioutas et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention Insights From the AUGUSTUS Trial
Stephan Windecker et al.
CIRCULATION (2019)
Strategies in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants (NOACs) and co-medications with possible drug-drug interaction
Tatjana Potpara et al.
EUROPEAN HEART JOURNAL (2019)
Levetiracetam and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and epilepsy: a reasonable combination
Tim J. von Oertzen et al.
EUROPEAN HEART JOURNAL (2019)
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
Pascal Vranckx et al.
LANCET (2019)
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
Satoshi Yasuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Poor concordance among drug compendia for proposed interactions between enzyme-inducing antiepileptic drugs and direct oral anticoagulants
Emily K. Acton et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2019)
Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation
So-Ryoung Lee et al.
STROKE (2019)
Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
Luis Alberto Garcia Rodriguez et al.
BMJ OPEN (2019)
TV-based assistive integrated service to support European adults living with mild dementia or mild cognitive impairment (TV-AssistDem): study protocol for a multicentre randomized controlled trial
Jessica Marian Goodman-Casanova et al.
BMC GERIATRICS (2019)
Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant
James D. Douketis et al.
JAMA INTERNAL MEDICINE (2019)
Outcome of Anticoagulation Therapy of Left Atrial Thrombus or Sludge in Patients With Nonvalvular Atrial Fibrillation or Flutter
Yankun Yang et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2019)
Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation
Sachin J. Shah et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2019)
Carotid Atherosclerosis in Patients with Atrial Fibrillation
Zhaojia Wang et al.
CURRENT ATHEROSCLEROSIS REPORTS (2019)
Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials
Giuseppe Gargiulo et al.
EUROPEAN HEART JOURNAL (2019)
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy A Nationwide Cohort Study
Hyunjean Jung et al.
CHEST (2019)
Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation Results From the GARFIELD-AF Registry
Jean-Pierre Bassand et al.
CIRCULATION (2019)
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
Giuseppe Boriani et al.
EUROPEAN HEART JOURNAL (2019)
Drug-drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants
Francois-Xavier Mathy et al.
EUROPEAN HEART JOURNAL (2019)
Challenges in clinical decision-making on concomitant drug therapies in patients with atrial fibrillation taking oral anticoagulants
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2019)
Stroke prevention in AF: Of Asians and non-Asians
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2019)
Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial
Tze-Fan Chao et al.
EUROPEAN HEART JOURNAL (2019)
Left Atrial or Left Atrial Appendage Thrombus Resolution After Adjustment of Oral Anticoagulant Treatment
Wei-Chieh Lee et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2019)
Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia
Chun-Li Wang et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation
David J. Seiffge et al.
LANCET NEUROLOGY (2019)
DELAYED INTRACRANIAL HEMORRHAGE IN ANTICOAGULATED GERIATRIC PATIENTS AFTER GROUND LEVEL FALLS
Alexandra T. Cocca et al.
JOURNAL OF EMERGENCY MEDICINE (2019)
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
William J. Powers et al.
STROKE (2019)
Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation
So-Ryoung Lee et al.
YONSEI MEDICAL JOURNAL (2019)
Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline
Catharina J. M. Klijn et al.
EUROPEAN STROKE JOURNAL (2019)
Safety of Apixaban Administered via Nasogastric Tube
Kevin Odell et al.
CARDIOLOGY (2019)
Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11-13 November 2018
Niaz Ahmed et al.
EUROPEAN STROKE JOURNAL (2019)
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study
Pierre Amarenco et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2019)
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKETAF
Sean T. Chen et al.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2019)
Thrombocytopenia: A possible side effect of apixaban
Farid Sadaka
CLINICAL CASE REPORTS (2019)
Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation
Simon Hellwig et al.
EUROPACE (2018)
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary
Hugh Calkins et al.
EUROPACE (2018)
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
Hugh Calkins et al.
EUROPACE (2018)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
Borja Ibanez et al.
EUROPEAN HEART JOURNAL (2018)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)
Marco Valgimigli et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2018)
2017 EACTS Guidelines on perioperative medication in adult cardiac surgery
Miguel Sousa-Uva et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2018)
Increased rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight and obese patients
Bhradeev Sivasambu et al.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2018)
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection
David J. Greenblatt et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians
J. Douxfils et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Microbleeds in ischemic vs hemorrhagic strokes on novel oral anticoagulants
J. C. Purrucker et al.
ACTA NEUROLOGICA SCANDINAVICA (2018)
Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial
Jean-Philippe Collet et al.
AMERICAN HEART JOURNAL (2018)
Feasibility of Left Atrial Appendage Occlusion for Left Atrial Appendage Thrombus in Patients With Persistent Atrial Fibrillation
Oh-Hyun Lee et al.
AMERICAN JOURNAL OF CARDIOLOGY (2018)
Drug-induced thrombocytopenia after anticoagulation with rivaroxaban
Marianne K. Pop et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2018)
Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial
Meena P. Rao et al.
AMERICAN JOURNAL OF MEDICINE (2018)
Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery
Michelle M. Graham et al.
ANNALS OF INTERNAL MEDICINE (2018)
Association of Prothrombin Complex Concentrate Administration and Hematoma Enlargement in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage
Stefan T. Gerner et al.
ANNALS OF NEUROLOGY (2018)
Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease
Joseph H. Schafer et al.
ANNALS OF PHARMACOTHERAPY (2018)
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Vittorio Pengo et al.
BLOOD (2018)
Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis
Zhen Ge et al.
CARDIOVASCULAR THERAPEUTICS (2018)
Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States
Konstantinos C. Siontis et al.
CIRCULATION (2018)
Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study
Tze-Fan Chao et al.
CIRCULATION (2018)
Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis
Deirdre A. Lane et al.
CLINICAL CARDIOLOGY (2018)
Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine
Justin D. Lutz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
European Heart RhythmAssociation (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?
Nikolaos Dagres et al.
EUROPACE (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary
Jan Steffel et al.
EUROPACE (2018)
Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe
Alexander C. Fanaroff et al.
EUROPEAN HEART JOURNAL (2018)
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
Michael D. Ezekowitz et al.
EUROPEAN HEART JOURNAL (2018)
Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2018)
A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation
J. Campbell Cowan et al.
EUROPEAN HEART JOURNAL (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119)
L. Tittl et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays
M. Jacquemin et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2018)
Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality
Taku Inohara et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia
Agnieszka Janion-Sadowska et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2018)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects
Wonkyung Byon et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Correlation of non-vitamin K antagonist oral anticoagulant exposure and cerebral microbleeds in Chinese patients with atrial fibrillation
Yannie Soo et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants: Comparison with Warfarin
Masahito Kawabori et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2018)
Prestroke Mobility and Dementia as Predictors of Stroke Outcomes in Patients Over 65 Years of Age: A Cohort Study From The Swedish Dementia and Stroke Registries
Sara Garcia-Ptacek et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2018)
Direct-acting oral anticoagulant drug level monitoring in clinical patient management
Amihai Rottenstreich et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2018)
Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial
Olivier Varenne et al.
LANCET (2018)
Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study
Marian Galovic et al.
LANCET NEUROLOGY (2018)
Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study
Duncan Wilson et al.
LANCET NEUROLOGY (2018)
Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin
Ryota Kurogi et al.
NEUROLOGY (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation
Jean-Pierre Bassand et al.
PLOS ONE (2018)
Age Threshold for Ischemic Stroke Risk in Atrial Fibrillation: Cohort Data Covering the Entire Korean Population
Tae-Hoon Kim et al.
STROKE (2018)
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Sam Schulman et al.
THROMBOSIS AND HAEMOSTASIS (2018)
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
Robert C. Gosselin et al.
THROMBOSIS AND HAEMOSTASIS (2018)
The effect of bariatric surgery on direct-acting oral anticoagulant drug levels
Amihai Rottenstreich et al.
THROMBOSIS RESEARCH (2018)
Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants: Comparison with Warfarin
Masahito Kawabori et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2018)
Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer
Kyu Kim et al.
KOREAN CIRCULATION JOURNAL (2018)
Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial
Nicolas M. Van Mieghem et al.
AMERICAN HEART JOURNAL (2018)
Safety of Edoxaban 30mg in Elderly Patients with Severe Renal Impairment
Giovanni Fazio et al.
CLINICAL DRUG INVESTIGATION (2018)
Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation The ENGAGE AF-TIMI 48 Trial
Ramon Corbalan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Edoxaban in Asian Patients With Atrial Fibrillation Effectiveness and Safety
So-Ryoung Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants The Stockholm Experience
Tomas Forslund et al.
STROKE (2018)
Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study
Giancarlo Agnelli et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study
Holger Reinecke et al.
BMJ OPEN (2018)
The Clinical Dilemma of Anticoagulation Use in Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation
Rocco J. Cannistraro et al.
CURRENT CARDIOLOGY REPORTS (2018)
2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
Jason G. Andrade et al.
CANADIAN JOURNAL OF CARDIOLOGY (2018)
Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan
Tze-Fan Chao et al.
CIRCULATION (2018)
Genetic Polymorphisms Associated with Spontaneous Intracerebral Hemorrhage
Yi-Chun Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding
Wayne A. Ray et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients The ARISTOPHANES Study
Gregory Y. H. Lip et al.
STROKE (2018)
Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs
Alessandro Galgani et al.
FRONTIERS IN NEUROLOGY (2018)
Efficacy and safety of dabigatran versus warfarin from the RE-LY trial
Alvaro Avezum et al.
OPEN HEART (2018)
Anticoagulation for atrial fibrillation after intracranial hemorrhage A systematic review
Maximiliano A. Hawkes et al.
NEUROLOGY-CLINICAL PRACTICE (2018)
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation
Surbhi Shah et al.
BLOOD ADVANCES (2018)
Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia
Phu Ngoc Tran et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2018)
Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis
Ying Bai et al.
AGE AND AGEING (2018)
Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC-TR
Sadik Volkan Emren et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2018)
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults
Kenneth Duchin et al.
CLINICAL PHARMACOKINETICS (2018)
Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation
Ken Okumura et al.
CLINICAL CARDIOLOGY (2017)
The prognosis of acute symptomatic seizures after ischaemic stroke
Thomas Leung et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey
Stefano Fumagalli et al.
EUROPACE (2017)
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE)
Gregory Y. H. Lip et al.
EUROPACE (2017)
Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study
Anne Godier et al.
EUROPEAN HEART JOURNAL (2017)
2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
Helmut Baumgartner et al.
EUROPEAN HEART JOURNAL (2017)
Atrial fibrillation as a risk factor for cognitive decline and dementia
Archana Singh-Manoux et al.
EUROPEAN HEART JOURNAL (2017)
Effects of dabigatran according to age in atrial fibrillation
Mandy N. Lauw et al.
HEART (2017)
Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants
Chan Soon Park et al.
HEART RHYTHM (2017)
Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran
Chen-Hung Lee et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation
Fernando Dominguez et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement
Julia Seeger et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2017)
Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
Shang-Hung Chang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis Effects of Weight Loss and Exercise
Carl J. Lavie et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease
Giulia Renda et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial
Raffaele De Caterina et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
Gordon F. Tomaselli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
The Changing Landscape for Stroke Prevention in AF Findings From the GLORIA-AF Registry Phase 2
Menno V. Huisman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Effect of New Oral Anticoagulants on Prescribing Practices for Atrial Fibrillation in Older Adults
Raymond B. Fohtung et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2017)
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
Thomas A. Mavrakanas et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study
Y. Song et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)
Hakeam A. Hakeam et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2017)
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
Dirk Sibbing et al.
LANCET (2017)
Incidence and management of seizures after ischemic stroke Systematic review and meta-analysis
Jeffrey Z. Wang et al.
NEUROLOGY (2017)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
Charles V. Pollack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
J. I. Weitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
Hugh Calkins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Falls, non-accidental falls and syncope in community-dwelling adults aged 50 years and older: Implications for cardiovascular assessment
Jaspreet Bhangu et al.
PLOS ONE (2017)
Incidence of seizures following initial ischemic stroke in a community-based cohort: The Framingham Heart Study
Maria Stefanidou et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2017)
Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? A Systematic Review and Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulant Trials
Marco Proietti et al.
STROKE (2017)
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation
Myung-Jin Cha et al.
STROKE (2017)
Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study
Anne G. Ording et al.
CANCER MEDICINE (2017)
Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update
Sang Joon An et al.
JOURNAL OF STROKE (2017)
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation A Review
John W. Eikelboom et al.
JAMA CARDIOLOGY (2017)
Non-vitamin-Koral anticoagulants and laboratory testing: now and in the future Views from a workshop at the European Medicines Agency (EMA)
Tomas Salmonson et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2017)
Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy
Ethan J. Rowin et al.
CIRCULATION (2017)
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
Benjamin A. Steinberg et al.
AMERICAN HEART JOURNAL (2017)
Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study
Ken Okumura et al.
AMERICAN HEART JOURNAL (2017)
Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial
Chiara Melloni et al.
AMERICAN JOURNAL OF MEDICINE (2017)
Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran
Parag Kumar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS2 Score ae 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?
Severine Henrard et al.
DRUGS & AGING (2017)
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
Ammar Majeed et al.
BLOOD (2017)
The impact of body weight on rivaroxaban pharmacokinetics
Sarah J. Barsam et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)
eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study
Nisha Bansal et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review
Theodore E. Warkentin et al.
BLOOD (2017)
The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review
Raffaele De Caterina et al.
CLINICAL RESEARCH IN CARDIOLOGY (2017)
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
Chern-En Chiang et al.
JOURNAL OF ARRHYTHMIA (2017)
Thrombocytopenia induced by dabigatran: two case reports
Hyun Goo Kang et al.
BMC NEUROLOGY (2017)
Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study
Yan Xu et al.
CHEST (2017)
Old and new oral anticoagulants: Food, herbal medicines and drug interactions
Alessandro Di Minno et al.
BLOOD REVIEWS (2017)
Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants An Observational Registry Analysis
Pierre Albaladejo et al.
ANESTHESIOLOGY (2017)
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial)
Somasekhara R. Balla et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance
Karlyn A. Martin et al.
AMERICAN JOURNAL OF MEDICINE (2017)
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy
Renato D. Lopes et al.
BLOOD (2017)
Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
W. Byon et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation
Paul L. Hess et al.
AMERICAN JOURNAL OF MEDICINE (2017)
Case report: apixaban-induced thrombocytopenia
Oliver Snellgrove
CLINICAL CASE REPORTS (2017)
Vascular Cognitive Impairment
Martin Dichgans et al.
CIRCULATION RESEARCH (2017)
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial
Raffaele De Caterina et al.
EUROPACE (2016)
Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
Andres Enriquez et al.
EUROPACE (2016)
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Marco Roffi et al.
EUROPEAN HEART JOURNAL (2016)
Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)
Gregory Y. H. Lip et al.
AMERICAN HEART JOURNAL (2016)
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
Robert P. Giugliano et al.
AMERICAN JOURNAL OF MEDICINE (2016)
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis
Clapton Dias et al.
AMERICAN JOURNAL OF NEPHROLOGY (2016)
Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression
Carmelo Scarpignato et al.
BMC MEDICINE (2016)
Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine
Dolly A. Parasrampuria et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers
Lori A. Gordon et al.
CIRCULATION (2016)
Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage
Tze-Fan Chao et al.
CIRCULATION (2016)
Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults
Yan Song et al.
CLINICAL THERAPEUTICS (2016)
Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs
Claudia Stoellberger et al.
EPILEPSY RESEARCH (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPACE (2016)
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial
Roopinder K. Sandhu et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Jose Luis Zamorano et al.
EUROPEAN HEART JOURNAL (2016)
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48
Giulia Magnani et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding
Wayne A. Ray et al.
GASTROENTEROLOGY (2016)
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease
Peter A. Noseworthy et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?
Ludovic Drouet et al.
INTERNATIONAL JOURNAL OF STROKE (2016)
Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation
Peter A. Noseworthy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling ENGAGE AF-TIMI 48 Analysis
Jan Steffel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
Kevin E. Chan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes The ORBIT-AF II Registry
Benjamin A. Steinberg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Obesity and risk of bleeding: the SMART study.
S. K. Braekkan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply
A. Tripodi
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
K. Martin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Allison E. Burnett et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2016)
Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage: A TQIP study
James M. Feeney et al.
JOURNAL OF TRAUMA AND ACUTE CARE SURGERY (2016)
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
Jeff S. Healey et al.
LANCET (2016)
Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery
A. M. Gillinov et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
C. Michael Gibson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin
Barbara S. Wiggins et al.
PHARMACOTHERAPY (2016)
Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study
Tze-Fan Chao et al.
STROKE (2016)
Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications
T. Jared Bunch et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage: A TQIP study
James M. Feeney et al.
JOURNAL OF TRAUMA AND ACUTE CARE SURGERY (2016)
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation
David J. Graham et al.
JAMA INTERNAL MEDICINE (2016)
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study
Gary Raskob et al.
LANCET HAEMATOLOGY (2016)
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine
John H. Alexander et al.
JAMA CARDIOLOGY (2016)
Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality The Atherosclerosis Risk in Communities (ARIC) Study
Jared W. Magnani et al.
JAMA CARDIOLOGY (2016)
Impact of the Direct Oral Anticoagulants on Activated Clotting Time
Anne-Sophie Dincq et al.
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA (2016)
The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial Fibrillation
Michelle Sholzberg et al.
PLOS ONE (2016)
Comparison of Safety of Left Atrial Catheter Ablation Procedures for Atrial Arrhythmias Under Continuous Anticoagulation With Apixaban Versus Phenprocoumon
Bernhard M. Kaess et al.
AMERICAN JOURNAL OF CARDIOLOGY (2015)
Dose-Finding Study of Rivaroxaban in Hemodialysis Patients
An S. De Vriese et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Charles E. Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Alvaro Avezum et al.
CIRCULATION (2015)
Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
Kevin E. Chan et al.
CIRCULATION (2015)
Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment
Yukihiro Koretsune et al.
CIRCULATION JOURNAL (2015)
The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
Jeanne Mendell et al.
CLINICAL DRUG INVESTIGATION (2015)
Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESCWorking Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS)
Christian Sticherling et al.
EUROPACE (2015)
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
Hein Heidbuchel et al.
EUROPACE (2015)
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
J. Steffel et al.
EUROPEAN HEART JOURNAL (2015)
Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
Riccardo Cappato et al.
EUROPEAN HEART JOURNAL (2015)
Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study
Esther W. Chan et al.
GASTROENTEROLOGY (2015)
Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study
Luigi Di Biase et al.
HEART RHYTHM (2015)
Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation
Li Hao et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule
Dolly A. Parasrampuria et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation
A. M. Shields et al.
JOURNAL OF INTERNAL MEDICINE (2015)
Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation A Nationwide Cohort Study From Taiwan
Tze-Fan Chao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH
G. D. Barnes et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Christian T. Ruff et al.
LANCET (2015)
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
James D. Douketis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk
Philip Urban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Marc P. Bonaca et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives
Alessandro Di Minno et al.
THROMBOSIS RESEARCH (2015)
The pooled incidence of post-stroke seizure in 102 008 patients
Safeng Zou et al.
TOPICS IN STROKE REHABILITATION (2015)
Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials
Subodh Verma et al.
BMC SURGERY (2015)
Monitoring and reversal of direct oral anticoagulants
Adam Cuker et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2015)
Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study
Leif Friberg et al.
EUROPEAN HEART JOURNAL (2015)
Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
David J. Graham et al.
CIRCULATION (2015)
Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate
Hamim Zahir et al.
CIRCULATION (2015)
Vitamin K Antagonists Predispose to Calciphylaxis in Patients width End-Stage Renal Disease
Peter A. G. Galloway et al.
NEPHRON (2015)
Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V
Takeshi Fuji et al.
THROMBOSIS JOURNAL (2015)
Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Shinya Goto et al.
AMERICAN HEART JOURNAL (2014)
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures
David Garcia et al.
BLOOD (2014)
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
Jan Beyer-Westendorf et al.
BLOOD (2014)
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
Charles Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis
Mitesh Shah et al.
CIRCULATION (2014)
Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management Results From the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial
Luigi Di Biase et al.
CIRCULATION (2014)
Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jonathan L. Halperin et al.
CIRCULATION (2014)
Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation
Matthew W. Sherwood et al.
CIRCULATION (2014)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2014)
Dementia and Cognitive Impairment Epidemiology, Diagnosis, and Treatment
Julie Hugo et al.
CLINICS IN GERIATRIC MEDICINE (2014)
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
Sigrun Halvorsen et al.
EUROPEAN HEART JOURNAL (2014)
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial
Jonathan P. Piccini et al.
EUROPEAN HEART JOURNAL (2014)
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
Gunter Breithardt et al.
EUROPEAN HEART JOURNAL (2014)
Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry
Jan Beyer-Westendorf et al.
EUROPEAN HEART JOURNAL (2014)
Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state
Claudia Stoellberger et al.
HEART & LUNG (2014)
Acute Thrombocytopenia after Initiating Anticoagulation with Rivaroxaban
Yohei Mima et al.
INTERNAL MEDICINE (2014)
Direct Oral Anticoagulants New Drugs and New Concepts
Jerrold H. Levy et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2014)
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF
I. G. Girgis et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
Paul A. Reilly et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Net Clinical Benefit of Antithrombotic Therapy in Patients With Atrial Fibrillation and Chronic Kidney Disease A Nationwide Observational Cohort Study
Anders Nissen Bonde et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants
Adam Cuker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
Elaine M. Hylek et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient
Apostolos Safouris et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers
M. Levi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Aspirin in Patients Undergoing Noncardiac Surgery
P. J. Devereaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Laura Mauri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
New Oral Anticoagulants and the Cancer Patient
Nicholas J. Short et al.
ONCOLOGIST (2014)
Warfarin Dosing Changes After Bariatric Surgery: Implications on the Mechanism for Altered Dose Requirements and Safety Concerns-An Alternative Viewpoint
Lingtak-Neander Chan
PHARMACOTHERAPY (2014)
Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial
Ka Sing Lawrence Wong et al.
STROKE (2014)
Vitamin K Antagonists and Risk of Subdural Hematoma Meta-Analysis of Randomized Clinical Trials
Ben J. Connolly et al.
STROKE (2014)
Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48
Robert P. Giugliano et al.
STROKE (2014)
Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation
Graeme J. Hankey et al.
STROKE (2014)
Point-of-Care Coagulation Testing for Assessment of the Pharmacodynamic Anticoagulant Effect of Direct Oral Anticoagulant
Helen Mani et al.
THERAPEUTIC DRUG MONITORING (2014)
Patient outcomes using the European label for dabigatran A post-hoc analysis from the RE-LY database
Gregory Y. H. Lip et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial
Takeshi Fuji et al.
THROMBOSIS RESEARCH (2014)
Rivaroxaban Crushed Tablet Suspension Characteristics and Relative Bioavailability in Healthy Adults When Administered Orally or Via Nasogastric Tube
Kenneth T. Moore et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2014)
Warfarin dosing after bariatric surgery: a retrospective study of 10 patients previously stable on chronic warfarin therapy
A. M. Schullo-Feulner et al.
CLINICAL OBESITY (2014)
Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
Raul Altman et al.
THROMBOSIS JOURNAL (2014)
Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
Jeanne Mendell et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2013)
Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people
Olivier Hanon et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2013)
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
Vijay V. Upreti et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
Charles Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
Wolfgang Mueck et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAMe-TT2R2 Score
Stavros Apostolakis et al.
CHEST (2013)
Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial
Antonio L. Dans et al.
CIRCULATION (2013)
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Ammar Majeed et al.
CIRCULATION (2013)
Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation
Mohamed Bassiouny et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2013)
Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation Insights From ROCKET AF
Sean van Diepen et al.
CIRCULATION-HEART FAILURE (2013)
Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial
John J. V. McMurray et al.
CIRCULATION-HEART FAILURE (2013)
Apixaban as an Alternate Oral Anticoagulant for the Management of Patients With Heparin-Induced Thrombocytopenia
Jeanine M. Walenga et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2013)
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
Hein Heidbuchel et al.
EUROPACE (2013)
Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation
Hany S. Abed et al.
HEART RHYTHM (2013)
Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients
Yu-feng Hu et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients With Atrial Fibrillation A Randomized Clinical Trial
Hany S. Abed et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting: Is There Any Benefit? A Systematic Review and Meta-Analysis
Salil V. Deo et al.
JOURNAL OF CARDIAC SURGERY (2013)
The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor
Jeanne Mendell et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2013)
Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
T. Baglin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Comparison of initial warfarin response in obese patients versus non-obese patients
Jessica L. Wallace et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2013)
Ischemic Stroke in an Obese Patient Receiving Dabigatran
Lorenz Breuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
John W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Warfarin Users Prone to Coagulopathy in First 30 Days After Hospital Discharge from Gastric Bypass
Peter Bechtel et al.
OBESITY SURGERY (2013)
A Review of Potential Harmful Interactions between Anticoagulant/Antiplatelet Agents and Chinese Herbal Medicines
Hsin-Hui Tsai et al.
PLOS ONE (2013)
Preventing Stroke in Patients With Chronic Kidney Disease and Atrial Fibrillation Benefit and Risks of Old and New Oral Anticoagulants
Holger Reinecke et al.
STROKE (2013)
Dabigatran Versus Warfarin Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation
Masatsugu Hori et al.
STROKE (2013)
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Racial Differences in the Prevalence and Outcomes of Atrial Fibrillation Among Patients Hospitalized With Heart Failure
Kevin L. Thomas et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
The transport of antiepileptic drugs by P-glycoprotein
Chunbo Zhang et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran
Joanne van Ryn et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model
Anne Godier et al.
ANESTHESIOLOGY (2012)
Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies
Krystin Krauel et al.
BLOOD (2012)
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding
Theodore E. Warkentin et al.
BLOOD (2012)
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial
Jeff S. Healey et al.
CIRCULATION (2012)
Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial
Harriette G. C. Van Spall et al.
CIRCULATION (2012)
Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation - The J-ROCKET AF Study
Masatsugu Hori et al.
CIRCULATION JOURNAL (2012)
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation
Stephen Andrew LaHaye et al.
EUROPEAN HEART JOURNAL (2012)
Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2012)
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial
Stefan H. Hohnloser et al.
EUROPEAN HEART JOURNAL (2012)
Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects
D. Kubitza et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model
I. Pragst et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
Jonas Bjerring Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Left Atrial Catheter Ablation and Ischemic Stroke
Karl Georg Haeusler et al.
STROKE (2012)
Poor Prognosis in Warfarin-Associated Intracranial Hemorrhage Despite Anticoagulation Reversal
Dar Dowlatshahi et al.
STROKE (2012)
Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice
Menno V. Huisman et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
Daniel E. Salazar et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature
Jonathan Douxfils et al.
THROMBOSIS RESEARCH (2012)
Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach
James D. Douketis
BLOOD (2011)
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
John W. Eikelboom et al.
CIRCULATION (2011)
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Elise S. Eerenberg et al.
CIRCULATION (2011)
Rivaroxaban Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2011)
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2011)
Non-cardiac surgery in patients with coronary stents: the RECO study
Pierre Albaladejo et al.
HEART (2011)
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban
Kenneth Todd Moore et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
The effect of antiepileptic drugs on coagulation and bleeding in the perioperative period of epilepsy surgery: The Cleveland Clinic experience
Crystal Manohar et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2011)
Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers
Jeanne Mendell et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Mark Jean Gnoth et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
K-H Liesenfeld et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Incidence and predictors of acute symptomatic seizures after stroke
E. Beghi et al.
NEUROLOGY (2011)
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Exposure to CYP3A4-inducing and CYP3A4-non-inducing antiepileptic agents and the risk of fractures
Hedi Schelleman et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Early treatment after stroke for the prevention of late epileptic seizures: A report on the problems performing a randomised placebo-controlled double-blind trial aimed at anti-epileptogenesis
J. H. van Tuijl et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2011)
Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran
Wei Zhou et al.
STROKE (2011)
Apixaban versus enoxaparin in patients with total knee arthroplasty A meta-analysis of randomised trials
Jiahao Huang et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) A randomised, double-blind, non-inferiority trial
Bengt I. Eriksson et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)
Elsayed Z. Soliman et al.
AMERICAN HEART JOURNAL (2010)
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate An Open-Label, Parallel-Group, Single-Centre Study
Joachim Stangier et al.
CLINICAL PHARMACOKINETICS (2010)
In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies
Lifei Wang et al.
DRUG METABOLISM AND DISPOSITION (2010)
Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
Koichiro Ogata et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
S. Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
The Development and Validation of a Brief Performance-Based Fall Risk Assessment Tool for Use in Primary Care
Anne Tiedemann et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mexican Americans With Atrial Fibrillation Have More Recurrent Strokes Than Do Non-Hispanic Whites
Jennifer R. Simpson et al.
STROKE (2010)
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study
Hiroshi Watanabe et al.
AMERICAN HEART JOURNAL (2009)
Incidence of atrial fibrillation in whites and African-Americans: The Atherosclerosis Risk in Communities (ARIC) study
Alvaro Alonso et al.
AMERICAN HEART JOURNAL (2009)
Coadministration of Dabigatran Etexilate and Atorvastatin Assessment of Potential Impact on Pharmacokinetics and Pharmacodynamics
Joachim Stangier et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2009)
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
John H. Alexander et al.
CIRCULATION (2009)
Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Alan S. Go et al.
CIRCULATION (2009)
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
Bengt I. Eriksson et al.
CLINICAL PHARMACOKINETICS (2009)
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Nirmala Raghavan et al.
DRUG METABOLISM AND DISPOSITION (2009)
Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure
Dale C. Hesdorffer et al.
EPILEPSIA (2009)
Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure
Jonathan P. Piccini et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Dilemmas in the Management of Atrial Fibrillation in Chronic Kidney Disease
Holger Reinecke et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Alexander G. G. Turpie et al.
LANCET (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Use of Stroke Secondary Prevention Services Are There Disparities in Care?
Joseph S. Ross et al.
STROKE (2009)
Chronic atrial fibrillation:: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme
Stephan Rietbrock et al.
AMERICAN HEART JOURNAL (2008)
Rivaroxaban - an oral, direct Factor Xa inhibitor - has potential for the management of patients with heparin-induced thrombocytopenia
Jeanine M. Walenga et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
Joachim Stangier et al.
CLINICAL PHARMACOKINETICS (2008)
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
Joachim Stangier
CLINICAL PHARMACOKINETICS (2008)
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
Dagmar Kubitza et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Ajay K. Kakkar et al.
LANCET (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
Bengt I. Eriksson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
Michael R. Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Warfarin Resistance After Total Gastrectomy and Roux-en-Y Esophagojejunostomy
Diana M. Sobieraj et al.
PHARMACOTHERAPY (2008)
Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation
Albert Yuh-Jer Shen et al.
STROKE (2008)
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2008)
Dabigatran with or without concomitant Aspirin compared with Warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study)
Michael D. Ezekowitz et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial
B. I. Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
Joachim Stangier et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation
Albert Yuh-Jer Shen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
Dagmar Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP
Sung B. Lee et al.
NEUROLOGY (2006)
Falls in older people: epidemiology, risk factors and strategies for prevention
Laurence Z. Rubenstein
AGE AND AGEING (2006)
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
D Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation
E Birman-Deych et al.
STROKE (2006)
Translating the results of randomized trials into clinical practice - The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation
EM Hylek et al.
STROKE (2006)
Post-stroke seizure and post-stroke epilepsy
P. K. Myint et al.
POSTGRADUATE MEDICAL JOURNAL (2006)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
A global clinical measure of fitness and frailty in elderly people
K Rockwood et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2005)
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement
J Stangier et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
The influence of extreme body weight on clinical outcome of patients with venous thromboembolism:: findings from a prospective registry (RIETE)
R Barba et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Obesity and the risk of new-onset atrial fibrillation
TJ Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Oral anticoagulation in surgical procedures: risks and recommendations
M Torn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Frailty in older adults: Evidence for a phenotype
LP Fried et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2001)
How long after drug ingestion is activated charcoal still effective?
R Green et al.
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY (2001)
Glomerular hemodynamics in severe obesity
A Chagnac et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2000)
Share Paper
